Compare Biogen Inc (BIIB) vs Heron Therapeutics Inc (HRTX) Price & Performance

Biogen (BIIB) trades at $210.65, up 3.32% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 37.1 and net income margin of 8.32%, supported by positive cash flow trends. Recent news highlights the acquisition of RayThera Inc. and raised 2026 guidance, reflecting strategic growth initiatives.

Outlook is positive with analyst consensus price target of $234.47, though risks include competitive pressures and earnings volatility. Investment opportunity lies in pipeline expansion and Alzheimer's drug traction, balanced by margin compression concerns from legacy MS portfolio declines.

HRTX trades at $0.34, up 5.28% today, but remains in a bearish technical trend with mixed earnings performance. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite strong analyst buy ratings (94.7%), fundamental challenges persist with negative net income margins and elevated valuation ratios.

The outlook remains cautious due to ongoing losses and competitive pressures, though institutional support and product revenue growth provide some stability. Key risks include patent litigation outcomes and the need for sustained revenue acceleration to achieve profitability.